Search results for "GFR"

showing 10 items of 206 documents

Time-course of GDNF and its receptor expression after brain injury in the rat

2008

Abstract The aim of the present work was to perform, by in situ hybridization, a time-course analysis of the glial cell line-derived neurotrophic factor (GDNF) and its receptor mRNA expression in two models of brain injury in the rat: (a) excitotoxic lesion by ibotenic acid injection in the hippocampal formation; (b) mechanical lesion by needle insertion through the cerebral cortex including the white matter of the corpus callosum. The time-course analysis, ranging from 6 h to 8 days, showed that the GDNF and its receptor (RET, GFRα-1 and GFRα-2) mRNA expressions were differentially up-regulated in both models of lesion. This in vivo regulation of the GDNF and its receptor mRNA expression i…

MalePathologymedicine.medical_specialtyGlial Cell Line-Derived Neurotrophic Factor ReceptorsTime FactorsReceptor expressionCentral nervous systemBiologyHippocampal formationSettore BIO/09 - FisiologiaLesionchemistry.chemical_compoundNeurotrophic factorsGlial cell line-derived neurotrophic factormedicineAnimalsGlial Cell Line-Derived Neurotrophic FactorRNA MessengerRats WistarIbotenic AcidGeneral NeuroscienceGDNF RET GFRalfa-1 GFRalfa-2 Brain injury In situ hybridizationRatsmedicine.anatomical_structureGene Expression Regulationnervous systemchemistryCerebral cortexBrain Injuriesbiology.proteinAutoradiographymedicine.symptomIbotenic acidNeuroscience Letters
researchProduct

Nicotine-induced fibroblast growth factor-2 restores the age-related decline of precursor cell proliferation in the subventricular zone of rat brain.

2007

Precursor cell proliferation is present in the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus of the hippocampus of adult rat and persists during aging although at reduced levels. Previous studies have shown that acute intermittent nicotine treatment significantly increases fibroblast growth factor-2 (FGF-2) expression in several brain regions of aged rats. The aim of the present investigation was to test the hypothesis that nicotine-induced expression of FGF-2 may restore the age-related decline of precursor cell proliferation. It was first demonstrated that nicotine treatment increases both mRNA and protein FGF-2 in the SVZ of aged …

Malemedicine.medical_specialtyAgingNicotineBasic fibroblast growth factorSubventricular zoneCell CountNerve Tissue ProteinsBiologyFibroblast growth factorSettore BIO/09 - FisiologiaAntibodiesSubgranular zoneNestinchemistry.chemical_compoundIntermediate Filament ProteinsInternal medicinePrecursor cellLateral VentriclesGlial Fibrillary Acidic ProteinmedicineAnimalsNicotinic AgonistsRats WistarMolecular BiologyCell ProliferationAnalysis of VarianceCell growthGeneral NeuroscienceDentate gyrusFibroblast growth factor receptor 1BrainPrecursor proliferationFGF-2 FGFR1 SVZ Nicotine AgedRatsAdult Stem CellsEndocrinologymedicine.anatomical_structurenervous systemchemistryBromodeoxyuridineGene Expression RegulationFibroblast Growth Factor 2Neurology (clinical)Developmental BiologyBrain research
researchProduct

Differential cystine and dibasic amino acid handling after loss of function of the amino acid transporter b0,+ AT (Slc7a9) in mice

2013

Cystinuria is an autosomal recessive disease caused by mutations in SLC3A1 ( rBAT) and SLC7A9 ( b 0,+ AT). Gene targeting of the catalytic subunit ( Slc7a9) in mice leads to excessive excretion of cystine, lysine, arginine, and ornithine. Here, we studied this non-type I cystinuria mouse model using gene expression analysis, Western blotting, clearance, and brush-border membrane vesicle (BBMV) uptake experiments to further characterize the renal and intestinal consequences of losing Slc7a9 function. The electrogenic and BBMV flux studies in the intestine suggested that arginine and ornithine are transported via other routes apart from system b0,+. No remarkable gene expression changes were…

Malemedicine.medical_specialtyPeptide transporterArgininePhysiologyLysineCystineSLC7A9BiologyKidneyGFRMicechemistry.chemical_compoundInternal medicinemedicineAnimalsAmino acid transporterMice Knockoutchemistry.chemical_classificationKidneyCystinuriaAmino Acids DiaminoCystinuriaOrnithinemedicine.diseaseAmino acidMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureEndocrinologychemistryBiochemistryAmino Acid Transport Systems BasicCystineGlomerular Filtration Rate
researchProduct

Structural performances of pultruded GFRP emergency structures – Part 1: Experimental characterization of materials and substructure

2019

Abstract This paper presents an experimental study in the field of structures made of pultruded fiber reinforced polymers (FRP) elements to be used for emergency purposes. A preliminary design of a 3D pultruded glass fiber reinforced polymer structure is presented with the mechanical characterization of the constituting elements. The axial and flexural properties of laminate and I-shaped GRFP profiles are discussed considering the short term creep. In a companion paper, the benefits, the limits and the reliability of the structure analyzed for emergency applications are discussed. In details, the numerical structural analysis of the full-scale 3D model is described followed by the experimen…

Materials science/dk/atira/pure/subjectarea/asjc/2200/2205Experimental testsGlass-fibre-reinforced polymer GFRP pultruded profileFlexural strengthEmergency structureExperimental testPultrusionFiber/dk/atira/pure/subjectarea/asjc/2500/2503Civil and Structural EngineeringComposite structuresbusiness.industryGlass fiber reinforced polymerStructural engineeringFibre-reinforced plasticCharacterization (materials science)Emergency structuresSettore ICAR/09 - Tecnica Delle CostruzioniSettore ING-IND/22 - Scienza E Tecnologia Dei MaterialiCreepPultrusionComposite structureCeramics and CompositesSubstructurebusinessGlass-fibre-reinforced polymer GFRP pultruded profiles
researchProduct

Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d[pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2

2015

Vascular Endothelial Growth Factor (VEGF) pathway has emerged as one of the most important positive modulators of Angiogenesis, a central process implicated in tumour growth and metastatic dissemination. This led to the design and development of anti-VEGF monoclonal antibodies and small-molecule ATP-competitive VEGFR-inhibitors. In this study, we describe the synthesis and the biological evaluation of novel 2-aryl substituted benzothiopyrano-fused pyrimidines 1a-i, 2a-i and 3a-i. The ability of the compounds to target the VEGF pathway was determined in vitro exploiting the compounds' antiproliferative efficacy against HUVEC cells. The VEGFR-2 inhibition was confirmed by enzymatic assays on …

Models MolecularAngiogenesisReceptor tyrosine kinaseCellAntineoplastic AgentsReceptor tyrosine kinaseBenzothiopyranopirimidines; Kinase inhibitors; Receptor tyrosine kinases; Tumor angiogenesis; VEGFR;Tumor angiogenesisStructure-Activity Relationshipchemistry.chemical_compoundVEGFRBenzothiopyranopirimidineCell Line TumorReceptor tyrosine kinasesDrug DiscoveryHuman Umbilical Vein Endothelial CellsmedicineHumansProtein Kinase InhibitorsCell ProliferationPyransTumor angiogenesiPharmacologyKinase inhibitorDose-Response Relationship DrugMolecular StructurebiologyKinaseCell growthOrganic ChemistryKinase insert domain receptorGeneral MedicineVascular Endothelial Growth Factor Receptor-2Molecular biologyVascular endothelial growth factorPyrimidinesmedicine.anatomical_structureBenzothiopyranopirimidineschemistryBenzothiopyranopirimidines; Kinase inhibitors; Receptor tyrosine kinases; Tumor angiogenesis; VEGFRKinase inhibitorsCancer researchbiology.proteinDrug Screening Assays AntitumorEx vivo
researchProduct

PROX1 transcription factor controls rhabdomyosarcoma growth, stemness, myogenic properties and therapeutic targets

2022

Funding Information: ACKNOWLEDGMENTS. We would like to thank Dr. Tuomas Tammela and Dr. Monika Ehnmann for providing RMS cell lines and Dr. Jenny Högström for discussions and comments during the project. Kirsi Mattinen, Jefim Brodkin, Maxime Laird, Manon Gruchet, Ilse Paetau, Tanja Laakkonen, and Tapio Tainola are acknowledged for their excellent technical help. We also thank the Laboratory Animal Center at the University of Helsinki for expert animal care, the Biomedicum Imaging Unit for microscope support, the Biomedicum Functional Genomics Unit for the RNAseq experiments and the FIMM Technology Centre High Throughput Biomedicine for the drug sensitivity and resistance testing. Our first …

MultidisciplinarysarcomaFGFRPROX13122 CancersGenes HomeoboxReceptors Fibroblast Growth FactorsarkoomaGene Expression RegulationRhabdomyosarcomaHumanscancersyöpätauditmyogenesis3111 BiomedicineChildTranscriptomeProtein Kinase InhibitorsTranscription Factors
researchProduct

Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project

2021

Abstract Background Hyperuricemia is commonly observed in patients with chronic kidney disease (CKD). However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification. Our main goal was to study the relationships between serum uric acid and kidney disease measures (namely estimated GFR [eGFR] and albuminuria) in a large cohort of individuals at cardiovascular risk from the URic acid Right for heArt Health (URRAH) Project database. Methods Clinica…

NephrologyAdultMalemedicine.medical_specialtySettore MED/09 - Medicina Interna030232 urology & nephrologyAllopurinolRenal functionHyperuricemia030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSerum uric acidRisk FactorsInternal medicineDiabetes mellitusmedicineeGFRHumansAlbuminuriaHyperuricemiaRenal Insufficiency ChronicAgedbusiness.industryAlbuminuria; Cardiovascular risk; Serum uric acid; eGFRnutritional and metabolic diseaseseGFR.Middle Agedmedicine.diseaseCardiovascular riskUric AcidchemistryNephrologyAlbuminuriaUric acidAlbuminuria; Cardiovascular risk; eGFR; Serum uric acidOriginal ArticleFemalemedicine.symptombusinessmedicine.drugKidney diseaseGlomerular Filtration Rate
researchProduct

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithel…

2015

Abstract Purpose: The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of MEHD7945A. Experimental Design: Patients with locally advanced or metastatic epithelial tumors received escalating doses of MEHD7945A (1–30 mg/kg) every 2 weeks (q2w) until disease progression or intolerable toxicity. An expansion cohort was enrolled at the recommended phase II dose (14 mg/kg, q2w). Plasma samples, tumor biopsies, FDG-PET were obtained for assessment of pharmacokinetics, and pharmacodynamic modulation downstream of EGFR and HER3. …

OncologyAdultMaleCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsReceptor ErbB-3Colorectal cancerCetuximabPharmacologyAntibodies Monoclonal HumanizedEGFR AntibodyArticleErlotinib HydrochloridePharmacokineticsInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaPanitumumabHumansAgedDose-Response Relationship Drugbusiness.industrySquamous Cell Carcinoma of Head and NeckPanitumumabCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseErbB ReceptorsOncologyHead and Neck NeoplasmsPharmacodynamicsImmunoglobulin GCarcinoma Squamous CellChillsFemalemedicine.symptombusinessmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research

2010

Breast cancer is a heterogeneous disease with different morphologies, molecular profiles, clinical behaviour and response to therapy. The triple negative is a particular type of breast cancer defined by absence of oestrogen and progesterone receptor expression as well as absence of ERBB2 amplification. It is characterized by its biological aggressiveness, worse prognosis and lack of a therapeutic target in contrast with hormonal receptor positive and ERBB2+ breast cancers. Given these characteristics, triple-negative breast cancer is a challenge in today's clinical practice. A new breast cancer classification emerged recently in the scientific scene based in gene expression profiles. The ne…

OncologyCA15-3medicine.medical_specialtyMicroarrayReceptor ErbB-2business.industryCancerBreast NeoplasmsGeneral MedicineDiseasemedicine.diseaseBreast cancerReceptors EstrogenOncologyInternal medicinemedicineHumansFemaleRadiology Nuclear Medicine and imagingReceptors Progesteroneskin and connective tissue diseasesBreast cancer classificationbusinessTriple-negative breast cancerEGFR inhibitorsCancer Treatment Reviews
researchProduct

Abstract 3363: Pharmacodynamic (PD) assessment of drug activity in tumor tissue from patients (pts) enrolled in a Phase I study of MEHD7945A (MEHD), …

2013

Abstract Background Members of the human epidermal growth factor receptor (HER) family of oncogenes are often co-expressed and heterodimerized, suggesting that simultaneous blockade of multiple HER family receptors may be more effective than targeting single receptors. MEHD is a dual-action human IgG1 antibody that can bivalently bind to HER3 and EGFR and block ligand binding to either. FDG-PET imaging is a recognized method of assessing PD modulation with EGFR inhibitors in the clinic. HER3 and EGFR signaling via the MAPK and PI3K pathways can be monitored in tissue by examining phosphorylation of downstream markers. Methods A Phase 1, multicenter, open-label study was conducted to evaluat…

OncologyCancer ResearchPathologymedicine.medical_specialtybiologybusiness.industryCancermedicine.diseasemedicine.disease_causeOncologyInternal medicinePharmacodynamicsbiology.proteinMedicineImmunohistochemistryAnal cancerKRASAntibodybusinessReceptorEGFR inhibitorsCancer Research
researchProduct